Financial Results for the Year Ended March 31, 2011

<Supplement>

As of May 10, 2011

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for FY2010 Ended March 31, 2011 and Forecasts for FY2011 Ended March 31, 2012

(Amounts less than ¥100 million is rounded down.)

1. Summary of Financial Results for FY2010

[Billion yen]

Net Sales	409.5	FY-on-FY	4.7	1.2	%
Pharmaceuticals	400.2	FY-on-FY	4.4	1.1	%
Other Businesses	9.3	FY-on-FY	0.2	3.3	%

In the pharmaceuticals segment, net sales were ¥400.2 billion, up 1.1%, or ¥4.4 billion, year-on-year.
The domestic sales of ethical drugs were up 2.0%, or 7.0 billion, year-on-year, to ¥361.6 billion. Although NHI drug prices were revised in April 2010, favorable sales were recorded by such products as Remicade, an anti-TNFα monoclonal antibody; Maintate, a selective β1 antagonist; and Talion, a treatment for allergic disorders. In addition, higher sales were recorded by generic drugs as well as by JEBIK V, a freeze-dried, cell-culture derived Japanese encephalitis vaccine, which the government reinstated as a recommended vaccination in April 2010. In addition, following the Great East Japan Earthquake, there were rising concerns throughout Japan about the supply of pharmaceuticals. As a result, there was a temporary increase in orders for most pharmaceutical products, including those of the Company.
Overseas sales of ethical drugs were down 6.7%, or ¥1.5 billion, year-on-year, to ¥21.3 billion. Sales of OTC products increased 9.2%, or ¥0.4 billion, year-on-year.
Sales of others in pharmaceuticals were down 11.2%, or ¥1.4 billion, year-on-year, due to the decrease of one-time revenue from a licensing agreement and contracted manufacturing products.

The Principal Products and Businesses in Each Business Segment
Pharmaceuticals: Ethical drugs, over-the-counter-drugs
Other businesses: Fine chemicals, real-estate leasing, information services, advertising, etc

[Billion yen]

Operating Income	76.5	FY-on-FY	15.1	24.6	%

Net sales increased ¥4.7 billion, year-on-year. On the other hand, gross profit declined by ¥1.9 billion, year-on-year, to ¥254.9 billion due to the influence of NHI drug price revisions and other factors. The cost of sales ratio worsened by 1.2 percentage points, to 37.7%.
In R&D expenses, accompanying a change in a licensing contract, the Company made a one-time payment of about ¥10.0 billion in the previous fiscal year. Also, expenditures for overseas development projects have passed their peak level and started to decline. As a result, R&D expenses decreased by ¥17.2 billion year-on-year, to ¥65.7 billion. Ratio of R&D expenses to net sales was 16.1%, compared with 20.5% in the previous year.
As described above, due to the significant decrease of R&D expenses, SG&A expenses were down 8.7%, or ¥17.0 billion, to ¥178.3 billion.

[Billion yen]

Ordinary Income	76.6	FY-on-FY	15.0	24.4	%

Net Income	37.7	FY-on-FY	7.4	24.8	%

Due to the increase of operating income, ordinary income was up ¥15.0 billion, year-on-year, to ¥76.6 billion, and net income was up ¥7.4 billion, year-on-year, to ¥37.7 billion.
Extraordinary income was ¥0.6 billion, with major item including gain on sales of property, plant and equipment.
Extraordinary loss was ¥13.2 billion, with major items including loss on valuation of investment in securities of ¥8.0 billion, loss on disaster accompanying the Great East Japan Earthquake of ¥2.1 billion, impairment loss of ¥0.8 billion, and loss related to business suspension for Medway injection recombinant human serum albumin preparation of ¥0.7 billion. In the previous fiscal year, the Company recorded extraordinary losses of ¥10.7 billion, such as impairment loss accompanying head office relocation, restructuring expenses, and loss related to business suspension in regard to Medway injection.

2. Summary of Forecasts for FY2011

[Billion yen]

Net Sales	403.0	FY-on-FY	(6.5)	(1.6	%)
Operating Income	63.0	FY-on-FY	(13.5)	(17.7	%)
Ordinary Income	63.0	FY-on-FY	(13.6)	(17.8	%)
Net Income	35.5	FY-on-FY	(2.2)	(6.0	%)

3. Dividends

	FY2011 (Estimate)		FY2010	
	2nd Quarter	For the year	2nd Quarter	For the year
Dividends per Share (¥)	14	28	14	28
Dividends Payout Ratio	34.5%		32.9%	

Note: The dividend payout ratio is calculated using net income for the fiscal year (less amortization of goodwill) and annual dividends.

2 Consolidated Financial Indicators for FY2010

(Amounts less than ¥100 million is rounded down.)

1. Profit and Loss

(1) PL

[Billion yen]

	FY2010	FY-on-FY			Comparison to forecasts		
		FY2009	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %
Net sales	**409.5**	404.7	4.7	1.2	401.0	8.5	2.1
Cost of sales	**154.5**	147.8	6.7	4.6	154.0	0.5	0.4
Sales cost ratio	**37.7%**	36.5%			38.4%		
Gross operation profit	**254.9**	256.9	(1.9)	(0.8)	247.0	7.9	3.2
SG&A expenses	**178.3**	195.4	(17.0)	(8.7)	180.0	(1.6)	(0.9)
% of net sales	**43.6%**	48.3%			44.9%		
Operating income	**76.5**	61.4	15.1	24.6	67.0	9.5	14.3
Ordinary income	**76.6**	61.6	15.0	24.4	67.0	9.6	14.5
Extraordinary income	**0.6**	0.0	0.5	0.0	0.5	0.1	25.8
Extraordinary losses	**13.2**	10.7	2.4	0.0	7.5	5.7	76.2
Net income	**37.7**	30.2	7.4	24.8	35.5	2.2	6.3

(2) Sales by Business Segments

[Billion yen]

	FY2010	FY-on-FY			Comparison to forecasts			Notes [FY-on-FY comparison]
		FY2009	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %	
Pharmaceuticals	**400.2**	395.7	4.4	1.1	390.7	9.5	2.4	Ethical drugs domestic sales +7.0 Contracted manufacturing products (0.8) Licensing fee, etc. (0.6) See page 5, (7)Sales of Main Products
% Composition	**97.7%**	97.8%			97.4%			
[Domestic]	**[376.8]**	[371.0]	[5.7]	[1.6]	[366.0]	[10.8]	[3.0]	
[Overseas]	**[23.3]**	[24.6]	[(1.2)]	[(5.1)]	[24.7]	[(1.3)]	[(5.4)]	
Others	**9.3**	9.0	0.2	3.3	10.3	(0.9)	(9.6)	
% Composition	**2.3%**	2.2%			2.6%			
[Domestic]	**[6.9]**	[6.7]	[0.1]	[1.8]	[7.5]	[(0.5)]	[(7.8)]	
[Overseas]	**[2.3]**	[2.2]	[0.1]	[8.0]	[2.8]	[(0.4)]	[(14.5)]	
Total	**409.5**	404.7	4.7	1.2	401.0	8.5	2.1	Foreign sales ratio FY2009: 6.6% FY2010: 6.3% Average exchange rate FY2009, 1$= ¥93.72 FY2010, 1$= ¥87.32
% Composition	**100.0%**	100.0%			100.0%			
[Domestic]	**[383.7]**	[377.8]	[5.8]	[1.6]	[373.5]	[10.2]	[2.7]	
[Overseas]	**[25.7]**	[26.8]	[(1.0)]	[(4.1)]	[27.5]	[(1.7)]	[(6.3)]	

(3) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	FY2010	FY-on-FY			Comparison to forecasts			Notes [FY-on-FY comparison]
		FY2009	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %	
Cost of sales	**154.5**	147.8	6.7	4.6	154.0	0.5	0.4	Cost of sales ratio worsened due to NHI price revision, etc.
% of Net sales	**37.7%**	36.5%			38.4%			
SG&A expenses	**178.3**	195.4	(17.0)	(8.7)	180.0	(1.6)	(0.9)	
% of Net sales	**43.6%**	48.3%			44.9%			
R&D expenses	**65.7**	83.0	(17.2)	(20.8)	70.0	(4.2)	(6.0)	FY2009; License fee payment related to amendment agreement of MP-424, approx. ¥10.0 billion
% of Net sales	**16.1%**	20.5%			17.5%			
Except R&D expenses	**112.6**	112.3	0.2	0.2	110.0	2.6	2.4	
Labor cost	**52.5**	53.0	(0.5)	(1.0)	51.0	1.5	3.0	Decrease in retirement benefit expenses, etc.
Sales promotion expenses	**11.3**	11.9	(0.6)	(5.5)	11.8	(0.5)	(4.2)	Decrease due to business suspension
Amortization of goodwill*2	**10.1**	10.1	0.0	0.1	10.1	0.0	0.5	
Others	**38.6**	37.2	1.3	3.7	37.1	1.5	4.2	
Total labor cost	**88.6**	89.9	(1.3)	(1.5)	87.5	1.1	1.3	Decrease in retirement benefit expenses, etc.

*1: Published forecasts announced on October 29, 2010 in the financial results for 1st Half of FY2010

*2: Clear off 150.5 billion yen within 15 years.

(4) Non-operating Income and Expenses

[Billion yen]

	FY2010	FY2009	Increase (Decrease)	Notes
Non-operating income	**3.4**	3.7	(0.2)	
Interest income	**1.5**	1.7	(0.2)	
Dividend income	**0.7**	0.7	0.0	
Equity in earnings of income	**0.2**	0.4	(0.2)	
Rent income	**0.2**	0.2	0.0	
Others	**0.6**	0.4	0.1	
Non-operating expenses	**3.3**	3.5	(0.1)	
Foreign exchange losses	**1.4**	1.4	0.0	
Losses on disposal of property, plant and equipment	**0.4**	0.4	0.0	
Donations	**0.3**	0.3	0.0	
Others	**1.1**	1.2	0.0	

(5) Extraordinary Income and Losses

[Billion yen]

	FY2010	FY2009	Increase (Decrease)	Notes
Exordinary income	**0.6**	0.0	0.5	
Gains on sale of property, plant and equipment	**0.3**	-	0.3	
Reversal of past year patent royalties	**0.1**	-	0.1	
Gains on sale of investments in securities	**0.1**	0.0	0.0	
Extraordinary Losses	**13.2**	10.7	2.4	
Loss on valuation of investment in securities	**8.0**	0.2	7.7	
Loss related to disaster	**2.1**	-	2.1	Expenses related to Great East Japan Earthquake
Impairment loss	**0.8**	1.8	(1.0)	FY2009; Relocation of the head office, etc.
Loss related to business suspension	**0.7**	3.2	(2.5)	Expenses related to business suspension of BIPHA Corp.
Special retirement expenses	**0.4**	-	0.4	Additional retirement expenses accompanied with employment transfer
Loss on sales of property, plant and equipment	**0.3**	-	0.3	
Restructuring expenses	**0.1**	1.5	(1.4)	FY2009; Expenses to relocation of the head office, etc.
Provision for reserve for HCV litigaion	-	3.0	(3.0)	FY2009; Additional provision due to the increase in the number of plaintiffs subject to the relief
Others	**0.5**	0.8	(0.2)	

(6) Taxes

[Billion yen]

	FY2010	FY2009	Increase (Decrease)	Notes
Income before income taxes and minority interests	**64.1**	50.9	13.1	
Income taxes-current	**26.9**	24.8	2.1	
Income taxes-deferred	**(0.4)**	(2.7)	2.3	
Minority interests	**(0.1)**	(1.3)	1.1	
Net Income	**37.7**	30.2	7.4	

	FY2010	FY2009
Statutory tax rate	40.6%	40.6%
Adjustment		
Non-deductible expenses	2.7%	3.8%
Non-taxable devidend income, etc.	(2.0%)	(2.3%)
Adjustment for per capital inhabitants tax	0.2%	0.2%
Special deduction for R&D expenses	(7.7%)	(10.7%)
Amortization of goodwil	6.3%	8.0%
Elimination of dividends upon consolidation	1.7%	2.0%
Increase/decrease in valuation allowance	0.1%	2.4%
Others	(0.6%)	(0.8%)
Actual tax rate	41.3%	43.2%

(7) Sales of Main Products

[Billion yen]

	FY2010	FY-on-FY			Comparison to Forecasts		
		FY2009	Increase (Decrease)	Change %	Forecasts *1	Increase (Decrease)	Change %
Ethical drugs	**394.7**	390.7	4.0	1.0	385.4	9.3	2.4
Ethical drugs domestic sales	**361.6**	354.6	7.0	2.0	350.7	10.9	3.1
Remicade	**60.4**	47.1	13.2	28.1	60.7	(0.2)	(0.5)
Radicut	**28.7**	27.9	0.7	2.6	28.2	0.4	1.5
Ceredist	**18.0**	16.8	1.1	7.0	17.7	0.2	1.5
Anplag	**16.4**	18.3	(1.9)	(10.6)	15.9	0.4	3.0
Urso	**15.3**	16.2	(0.9)	(5.6)	15.0	0.3	2.3
Talion	**13.4**	10.6	2.7	26.2	12.5	0.8	6.8
Maintate	**12.3**	11.0	1.2	11.6	11.8	0.4	3.9
Depas	**11.4**	11.5	(0.1)	(1.2)	11.1	0.3	3.0
Tanatril	**9.6**	11.1	(1.4)	(13.2)	9.2	0.3	4.1
Herbesser	**9.6**	10.7	(1.1)	(10.6)	9.5	0.1	1.4
Venoglobulin IH	**9.6**	9.6	0.0	(0.2)	8.7	0.8	9.4
Liple	**7.3**	8.0	(0.7)	(8.8)	7.2	0.0	0.6
Sermion	**6.3**	7.2	(0.8)	(11.8)	6.3	0.0	0.3
Neuart	**5.5**	5.7	(0.1)	(2.4)	5.4	0.1	2.0
Omeprason	**4.8**	5.5	(0.6)	(11.7)	4.7	0.1	2.5
Novastan	**3.1**	2.8	0.2	8.4	3.1	0.0	(0.2)
BIKEN Products [Vaccine]*2	**29.6**	22.9	6.6	28.8	26.7	2.8	10.6
Mearubik	**12.2**	11.7	0.4	4.2	11.8	0.4	4.0
Influenza*2	**7.1**	6.3	0.7	12.1	7.2	(0.1)	(2.2)
JEVIK V	**6.9**	2.0	4.9	244.3	4.7	2.2	47.2
Tanabe Seiyaku Hanbai Products *3	**14.0**	8.5	5.5	64.8	13.4	0.5	4.2
Ethical drugs overseas sales	**21.3**	22.8	(1.5)	(6.7)	22.1	(0.7)	(3.6)
Herbesser	**4.6**	4.6	0.0	(0.3)	4.4	0.1	4.3
Argatroban (Novastan)	**3.4**	3.6	(0.1)	(4.4)	3.0	0.3	12.9
Tanatril	**1.8**	1.8	0.0	1.3	1.7	0.0	3.2
Anplag	**0.6**	1.1	(0.5)	(45.6)	0.9	(0.3)	(35.7)
Vaccine	**1.3**	1.3	0.0	2.5	1.3	0.0	0.5
Contracted manufacturing products *4	**9.3**	10.1	(0.8)	(8.0)	9.7	(0.3)	(3.4)
Lincensing Fee, etc.	**2.4**	3.1	(0.6)	(21.7)	2.9	(0.4)	(16.2)
OTC products	**5.4**	4.9	0.4	9.2	5.2	0.1	3.0
Total Pharmaceuticals	**400.2**	395.7	4.4	1.1	390.7	9.5	2.4

*1: Published forecasts announced on October 29, 2010 in the financial results for 1st Half of FY2010.

*2: In FY2009, sales of influenza(H1N1)2009 vaccine are not included in sales of vaccine and influenza vaccine.
Seasonal influenza vaccine in FY2010 is composed of influenza(H1N1)2009 vaccine and other seeds.

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which are transferred from MTPC.

*4: Active pharmaceutical ingredients, and others ordered by other compnies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of FY2010	Composition %	End of FY2009	Increase (Decrease)	Notes [Billion yen]
Total Aseets	**818.7**	**100.0**	796.8	21.8	
Current Assets	**391.5**	**47.8**	344.2	47.3	
Cash and deposits	**27.4**	**3.3**	22.7	4.6	See Page 7, ③ Statements of Cash Flows
Merketable securities	**84.7**	**10.4**	59.7	25.0	Increase of negotiable deposits
Notes and accounts receivable*1	**128.3**	**15.7**	126.2	2.1	
[Months/Revolution]	**[3.76]**		[3.74]	[0.02]	
Inventories	**77.7**	**9.5**	73.1	4.5	Increased of finished products such as Remicade
Deposits	**56.3**	**6.9**	46.2	10.0	Money deposited to MCFA, a group financing company of Mitsubishi Chemical Holdings
Deferred income taxes	**12.5**	**1.5**	11.3	1.1	
Others	**4.4**	**0.5**	4.6	(0.2)	
Fixed Assets	**427.1**	**52.2**	452.6	(25.4)	
Property, plant and equipment	**113.5**	**13.9**	117.2	(3.7)	Investment for plant and equipment, 10.1, Depreciation, (11.3)
Intangible fixed assets	**119.2**	**14.6**	129.6	(10.3)	Investment for information system, 0.8; Amortization of goodwill, (10.1); Depreciation, (1.0)
Investment in securities	**127.6**	**15.6**	139.1	(11.5)	Decrease due to market valuation
Prepaid pension expenses	**40.4**	**4.9**	36.7	3.7	
Other investments	**26.3**	**3.2**	29.9	(3.6)	
Total Liabilities	**122.7**	**15.0**	120.0	2.7	
Current Liabilities	**87.7**	**10.7**	77.7	9.9	
Notes and accounts payable*2	**29.6**	**3.6**	27.5	2.0	Increase in debts for Remicade and vaccine
Short-term debt	**2.8**	**0.4**	2.4	0.4	
Accrued payable	**20.3**	**2.5**	20.2	0.1	
Income taxes payable	**15.2**	**1.9**	11.0	4.1	
Other current liabilities	**19.6**	**2.4**	16.5	3.1	
Fixed Liabilities	**35.0**	**4.3**	42.2	(7.2)	
Deferred income taxes	**11.4**	**1.4**	11.2	0.1	
Accrued retirement benefits for employees	**11.8**	**1.4**	13.1	(1.3)	
Reserve for health management allowances for HIV compensation	**1.5**	**0.2**	1.6	(0.1)	
Reserve for health management allowances for SMON compensation	**3.8**	**0.5**	4.2	(0.3)	
Reserve for HCV litigation	**4.6**	**0.6**	10.6	(6.0)	Reversal accompanied with payment of the settlement
Other long-term liabilities	**1.7**	**0.2**	1.3	0.4	
Net Assets	**695.9**	**85.0**	676.8	19.1	
Shareholder's equity	**702.2**	**85.8**	680.3	21.8	
Common stock	**50.0**	**6.1**	50.0	-	
Capital surplus	**451.1**	**55.1**	451.1	0.0	
Retained earnings	**201.4**	**24.6**	179.4	22.0	Net income, 37.7 ; Payment for dividends, 15.7
Teasury stock	**(0.4)**	**(0.0)**	(0.2)	(0.1)	
Valuation and translation adjustments	**(12.0)**	**(1.5)**	(9.8)	(2.1)	
Unrealized holding gains on securities	**(2.7)**	**(0.3)**	(3.2)	0.5	
Deffered (losses) gains on hedges	**(1.0)**	**(0.1)**	(0.3)	(0.6)	
Translation adjustments	**(8.2)**	**(1.0)**	(6.2)	(2.0)	
Minority interests	**5.7**	**0.7**	6.3	(0.5)	

*1: Note and accounts receivable = Bills + Accounts receivable

*2: Note and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	FY2010	FY2009	Increase (Decrease)
Cash and cash equivalents at beginning of year	**62.9**	116.9	(53.9)
Cash flows from operating activities	**59.0**	23.9	35.1
Income before income taxes and minority interests	**64.1**	50.9	13.1
Depreciation and amortization	**12.4**	13.2	(0.8)
Impairment loss	**0.8**	1.8	(1.0)
Amortization of goodwill	**10.1**	10.1	0.0
Increase (decrease) in accrued retirement benefit for employees	**(1.2)**	(1.1)	(0.1)
Decrease (increase) in prepaid pension expenses	**(3.7)**	(1.2)	(2.4)
Increase (decease) in reserve for HCV litigation	**(6.0)**	(9.3)	3.2
Increase (decrease) in allowance for disaster	**1.5**	-	1.5
Interest and dividend income	**(2.3)**	(2.5)	0.1
Loss (gain) on sales of investments in securities	**8.0**	0.2	7.7
Decrease(increase) in notes and accounts receivable, trade	**(2.5)**	(3.1)	0.5
Decrease (increase) in inventories	**(4.7)**	(4.9)	0.1
Increase (decrease) in notes and accounts payable, trade	**2.4**	1.2	1.2
Increase(decrease) in accured expenses	**(2.1)**	0.4	(2.5)
Interest and dividends received	**2.5**	2.7	(0.1)
Income taxes paid	**(22.2)**	(29.1)	6.9
Other, net	**2.0**	(5.5)	7.5
Cash flows from investing activities	**(7.6)**	(61.2)	53.5
Purchase/sales etc. of marketable securities	**25.7**	(5.8)	31.5
Increase/decrease in time deposits	**(0.9)**	(8.7)	7.8
Increase/decrease in long-term deposits	**0.0**	(0.6)	0.6
Purchase/sales of property, plant and equipment	**(7.0)**	(8.1)	1.1
Purchase of intangible fixed assets	**(0.7)**	(1.0)	0.3
Purchase/sales of investment in securities	**(24.7)**	(42.3)	17.5
Other, net	**0.0**	5.5	(5.4)
Cash flows from financing activities	**(15.4)**	(17.1)	1.6
Increase (decrease) in short-term debt, net	**0.4**	(0.3)	0.8
Repayment of long-term loans debt	**0.0**	(0.9)	0.8
Cash dividends paid	**(15.7)**	(15.7)	0.0
Other, net	**(0.1)**	0.0	0.0
Effect of exchange rate change on cash and cash equivalents	**(1.1)**	0.2	(1.4)
Net increase (decrease) in cash and cash equivalents	**34.8**	(54.1)	88.9
Increase (decrease) in cash and cash equivalent resulting from merger with unconsolidated subsidiaries	**0.0**	0.1	(0.1)
Cash and cash equivalents at end of year	**97.8**	62.9	34.9

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	FY2010	FY2009
Cash and time deposits	27.4	22.7
Time deposits maturing after three months	(11.5)	(9.5)
Short-term investments in marketable securities maturing within three months of acquisition	25.4	3.1
Cash and cash equivalents included in short-term loans receivable*	0.1	0.3
Cash and cash equivalents included in deposits	56.3	46.2
Cash and cash equivalents in the consolidated statements of cash flows	97.8	62.9

*: short-term loans are included in "Others, Current Assets" on page 6.

(3) Investment in Property, Plant and Equipment and Investment for Development of Information Systems

[Billion yen]

	FY2010	FY2009	Increase (decrease)
Investment in property, plant and equipment /occuring basis	**10.1**	8.3	1.7
Investment for information systems/occuring basis	**0.8**	0.8	0.0

[Billion yen]

Major investment in property, plant and equipment in FY2010		Major investment for development of information systems in FY2010	
Mitsubishi Tanabe Pharma	4.6	Mitsubishi Tanabe Pharma	0.5
[Construction of a new research building at Yokohama Office]	[2.3]		
Mitsubishi Tanabe Pharma Factory	3.6		
[Manufacturing facilities at Kashima Plant]	[1.7]		
Benesis	1.1		
[Manufacturing facilities at Kyoto Plant]	[0.4]		

(4) Depreciation Costs

[Billion yen]

	FY2010	FY2009	Increase (decrease)
Property, plant and equipment	**11.3**	12.2	(0.9)
Intangible fixed assets	**1.0**	1.0	0.0

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

[Billion yen]

	Companies	Benesis Corporation	Mitsubishi Tanabe Pharma Factory Ltd.	Mitsubishi Tanabe Pharma Korea Co., Ltd.	Mitsubishi Pharma (Guangzhou) Co., Ltd.	Tianjin Tanabe Seiyaku Co., Ltd.
	Fiscal Year	End of March	End of March	End of December	End of December	End of December
Net Sales	FY2010	**18.2**	**53.0**	**3.7**	**2.2**	**2.0**
	FY2009	18.7	53.8	3.5	3.4	2.0
Operating Income	FY2010	**1.2**	**4.6**	**0.5**	**(0.1)**	**0.1**
	FY2009	1.6	2.5	0.6	0.5	0.1
Ordinary Income	FY2010	**1.3**	**4.5**	**0.5**	**(0.3)**	**0.1**
	FY2009	1.6	2.5	0.6	0.5	0.1
Net Income and Loss	FY2010	**0.8**	**2.3**	**0.4**	**(0.3)**	**0.1**
	FY2009	1.0	1.4	0.4	0.4	0.1
R&D Expenses	FY2010	**2.0**	**0.9**	**-**	**0.0**	**0.0**
	FY2009	2.3	1.1	-	0.0	0.0
Depreciation of Property, Plant and Equipment	FY2010	**1.0**	**3.8**	**0.0**	**0.1**	**0.0**
	FY2009	1.2	4.0	0.0	0.1	0.0
Total Assets	FY2010	**29.9**	**57.7**	**2.5**	**3.8**	**1.8**
	FY2009	29.0	57.9	2.5	4.9	1.8
Net Assets	FY2010	**25.0**	**38.6**	**1.5**	**3.2**	**1.4**
	FY2009	24.7	37.0	1.7	3.8	1.3
Number of Employees	FY2010	**575**	**1219**	**125**	**419**	**333**
	FY2009	569	1115	120	430	321

3 Forecasts for FY2011 Ending March 31, 2012

(Amounts less than ¥100 million is rounded down.)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	1st Half of FY2011 Forecasts	1st Half of FY2010 Actual	Increase (Decrease)	Change %	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %	Notes
Net Sales	**194.5**	204.6	(10.1)	(5.0)	**403.0**	409.5	(6.5)	(1.6)	
Cost of Sales	**75.5**	77.8	(2.3)	(3.0)	**150.5**	154.5	(4.0)	(2.6)	
Sales cost ratio	**38.8%**	38.0%			**37.3%**	37.7%			
Gross Operatin Profit	**119.0**	126.8	(7.8)	(6.2)	**252.5**	254.9	(2.4)	(1.0)	
SG & A Expenses	**96.5**	86.6	9.8	11.3	**189.5**	178.3	11.1	6.2	
% of Net Sales	**49.6%**	42.4%			**47.0%**	43.6%			
Operating Income	**22.5**	40.1	(17.6)	(44.0)	**63.0**	76.5	(13.5)	(17.7)	
Ordinary Income	**22.5**	40.4	(17.9)	(44.4)	**63.0**	76.6	(13.6)	(17.8)	
Extraordinary Income	**-**	0.4	(0.4)	-	**-**	0.6	(0.6)	-	
Extraordinary Losses	**0.5**	3.7	(3.2)	-	**1.0**	13.2	(12.2)	-	
Net Income	**11.5**	22.7	(11.2)	(49.3)	**35.5**	37.7	(2.2)	(6.0)	

(2) Sales Forecasts by Segments

[Billion yen]

	1st Half of FY2011 Forecasts	1st Half of FY2010 Actual	Increase (Decrease)	Change %	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %	Notes
Pharmaceuticals	**189.3**	199.8	(10.4)	(5.2)	**392.9**	400.2	(7.2)	(1.8)	
% Composition	**97.4%**	97.6%			**97.5%**	97.7%			
[Domestic]	**[178.1]**	[187.4]	[(9.3)]	[(5.0)]	**[368.7]**	[376.8]	[(8.1)]	[(2.2)]	
[Overseas]	**[11.2]**	[12.3]	[(1.1)]	[(9.3)]	**[24.2]**	[23.3]	[0.8]	[3.6]	
Other Businesses	**5.1**	4.8	0.2	5.5	**10.0**	9.3	0.7	7.9	
% Composition	**2.6%**	2.4%			**2.5%**	2.3%			
[Domestic]	**[3.6]**	[3.4]	[0.1]	[4.5]	**[7.2]**	[6.9]	[0.3]	[5.5]	
[Overseas]	**[1.4]**	[1.3]	[0.1]	[8.1]	**[2.7]**	[2.3]	[0.3]	[14.7]	
Total	**194.5**	204.6	(10.1)	(5.0)	**403.0**	409.5	(6.5)	(1.6)	Foreign sales ratio FY2010: 6.3% FY2011estimation: 6.7%
% Composition	**100.0%**	100.0%			**100.0%**	100.0%			
[Domestic]	**[181.8]**	[190.9]	[(9.1)]	[(4.8)]	**[376.0]**	[383.7]	[(7.7)]	[(2.0)]	Exchange rate planned: 1US$=¥85
[Overseas]	**[12.6]**	[13.7]	[(1.0)]	[(7.5)]	**[26.9]**	[25.7]	[1.1]	[4.7]	

(3) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	1st Half of FY2011 Forecasts	1st Half of FY2010 Actual	Increase (Decrease)	Change %	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %	Notes
Cost of Sales	**75.5**	77.8	(2.3)	(3.0)	**150.5**	154.5	(4.0)	(2.6)	
Sales cost ratio	**38.8%**	38.0%			**37.3%**	37.7%			
SG & A Expenses	**96.5**	86.6	9.8	11.3	**189.5**	178.3	11.1	6.2	
% of Net sales	**49.6%**	42.4%			**47.0%**	43.6%			
R&D Expenses	**36.0**	32.4	3.5	10.8	**69.0**	65.7	3.2	4.9	
% of Net sales	**18.5%**	15.9%			**17.1%**	16.1%			
Except R&D Expens	**60.5**	54.2	6.2	11.6	**120.5**	112.6	7.8	7.0	
Labor Cost	**25.6**	25.8	(0.2)	(0.9)	**51.3**	52.5	(1.2)	(2.3)	
Amortization of Goodwill *	**5.1**	5.0	0.0	0.6	**10.1**	10.1	0.0	(0.5)	
Others	**29.8**	23.3	6.4	27.8	**59.1**	49.9	9.1	18.3	
Total Labor Cost	**44.3**	44.0	0.2	0.6	**88.9**	88.6	0.2	0.3	Increase in sales promotion expenses accompanied with launch of new products

*: Clear off 150.5 billion yen within 15 years.

(4) Sales Forecasts for Main Products [Billion yen]

	1st Half of FY2011 Forecasts	1st Half of FY2010 Actual	Increase (Decrease)	Change %	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %
Ethical drugs	**186.6**	196.9	(10.3)	(5.2)	**387.7**	394.7	(7.0)	(1.8)
Ethical drugs domestic sales	**171.1**	179.1	(8.0)	(4.5)	**355.0**	361.6	(6.6)	(1.8)
Remicade	**-**	29.3	-	-	**-**	60.4	-	-
Radicut	**-**	14.2	-	-	**-**	28.7	-	-
Ceredist	**-**	8.9	-	-	**-**	18.0	-	-
Anplag	**-**	8.2	-	-	**-**	16.4	-	-
Urso	**-**	7.7	-	-	**-**	15.3	-	-
Talion	**-**	4.7	-	-	**-**	13.4	-	-
Maintate	**-**	5.9	-	-	**-**	12.3	-	-
Depas	**-**	5.7	-	-	**-**	11.4	-	-
Tanatril	**-**	4.9	-	-	**-**	9.6	-	-
Herbesser	**-**	4.8	-	-	**-**	9.6	-	-
Venoglobulin IH	**-**	4.5	-	-	**-**	9.6	-	-
Liple	**-**	3.7	-	-	**-**	7.3	-	-
Sermion	**-**	3.3	-	-	**-**	6.3	-	-
Neuart	**-**	2.7	-	-	**-**	5.5	-	-
Omeprason	**-**	2.4	-	-	**-**	4.8	-	-
Novastan	**-**	1.6	-	-	**-**	3.1	-	-
BIKEN Products [Vaccine]	**-**	15.0	-	-	**-**	29.6	-	-
[Mearubik]	**-**	7.5	-	-	**-**	12.2	-	-
[Influenza]	**-**	1.9	-	-	**-**	7.1	-	-
[JEVIK V]	**-**	3.7	-	-	**-**	6.9	-	-
Tanabe Seiyaku Hanbai Products *1	**-**	5.4	-	-	**-**	14.0	-	-
Ethical drugs overseas sales	**9.0**	11.2	(2.2)	(19.7)	**18.9**	21.3	(2.3)	(11.2)
Herbesser	**2.8**	2.4	0.3	15.5	**5.6**	4.6	0.9	20.5
Argatroban (Novastan)	**2.0**	1.8	0.2	11.8	**3.9**	3.4	0.4	13.9
Tanatril	**1.2**	0.9	0.2	28.0	**2.5**	1.8	0.6	37.4
Vaccine	**0.9**	0.6	0.2	36.0	**1.8**	1.3	0.4	32.9
Contracted manufacturing products *2	**4.1**	5.2	(1.0)	(20.1)	**8.3**	9.3	(1.0)	(11.5)
Lincensing Fee, etc.	**2.2**	1.3	0.9	73.4	**5.4**	2.4	3.0	123.7
OTC products	**2.7**	2.8	(0.1)	(4.6)	**5.2**	5.4	(0.2)	(3.8)
Total Pharmaceuticals	**189.3**	199.8	(10.4)	(5.2)	**392.9**	400.2	(7.2)	(1.8)

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which are transferred from MTPC.
*2: Active pharmaceutical ingredients, and others ordered by other compnies.

Sales Forecast for Domestic Main Products

The impacts related to the quality control incident in MTPF, which was announced in January 2011, and the Great East Japan Earthquake are uncertain. Accordingly, the Company has chosen not to disclose sales forecasts for domestic main products this time.

(5) Forecast of Investment for Property, Plant and Equipment and Information System

[Billion yen]

	1st Half of FY2011 Forecasts	1st Half of FY2010 Actual	Increase (decrease)	Change %	FY2011 Forecasts	FY2010 Actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occuring basis	4.4	3.9	0.5	14.2	7.7	10.1	(2.4)	(24.0)
Investment for information systems/occuring basis	0.3	0.3	0.0	(5.1)	1.0	0.8	0.1	22.1

[Billion yen]

Major investment in property, plant and equipment in FY2011		Major investment for information system in FY2011	
Production Facilities	4.5	R&D Related Systems	0.4
[Mitsubishi Tanabe Pharma Factory]	[1.5]	Production Related Systems	0.2
Facilities & Equipment for R&D	2.4	Others	0.4
Others	0.7		

(6) Forecasts for Depreciation Costs

[Billion yen]

	1st Half of FY2011 Forecasts	1st Half of FY2010 Actual	Increase (decrease)	Change %	FY2011 Forecasts	FY2010 Actual	Increase (decrease)	Change %
Property, plant and equipment	5.9	5.4	0.5	9.2	12.2	11.3	0.9	8.0
Intangible fixed assets	0.5	0.5	0.0	(5.1)	1.0	1.0	0.0	(4.9)

4 Quarterly Trend

(Amounts less than ¥100 million is rounded down.)

(1) Profit and Loss

[Billion yen]

	FY2009					FY2010				
	1Q Apr. to Jun.	2Q Jul. to Sep.	3Q Oct. to Dec.	4Q Jan. to Mar.	FY2009 Actual	1Q Apr. to Jun.	2Q Jul. to Sep.	3Q Oct. to Dec.	4Q Jan. to Mar.	FY2010 Actual
Net Sales	100.7	97.4	121.9	84.5	404.7	108.7	95.9	114.8	89.9	409.5
	24.9%	24.1%	30.1%	20.9%	100.0%	26.6%	23.4%	28.0%	22.0%	100.0%
[Domestic]	[94.5]	[90.2]	[115.6]	[77.5]	[377.8]	[102.0]	[88.9]	[108.9]	[83.8]	[383.7]
	[25.0%]	[23.9%]	[30.6%]	[20.5%]	[100.0%]	[26.6%]	[23.2%]	[28.4%]	[21.8%]	[100.0%]
[Overseas]	[6.2]	[7.2]	[6.3]	[6.9]	[26.8]	[6.7]	[6.9]	[5.9]	[6.1]	[25.7]
	[23.3%]	[27.0%]	[23.8%]	[26.0%]	[100.0%]	[26.1%]	[27.1%]	[22.9%]	[23.8%]	[100.0%]
Pharmaceuticals	98.1	95.2	119.6	82.6	395.7	106.0	93.8	112.5	87.8	400.2
	24.8%	24.1%	30.2%	20.9%	100.0%	26.5%	23.4%	28.1%	22.0%	100.0%
[Domestic]	[92.7]	[88.4]	[113.7]	[76.0]	[371.0]	[100.2]	[87.2]	[107.1]	[82.2]	[376.8]
	[25.0%]	[23.8%]	[30.7%]	[20.5%]	[100.0%]	[26.6%]	[23.2%]	[28.4%]	[21.8%]	[100.0%]
[Overseas]	[5.4]	[6.7]	[5.8]	[6.6]	[24.6]	[5.7]	[6.5]	[5.3]	[5.6]	[23.3]
	[22.0%]	[27.5%]	[23.7%]	[26.8%]	[100.0%]	[24.8%]	[28.1%]	[22.9%]	[24.2%]	[100.0%]
Others	2.5	2.2	2.3	1.8	9.0	2.7	2.0	2.3	2.1	9.3
	28.7%	24.6%	26.3%	20.4%	100.0%	29.6%	22.5%	25.3%	22.6%	100.0%
[Domestic]	[1.7]	[1.7]	[1.8]	[1.4]	[6.7]	[1.8]	[1.6]	[1.8]	[1.6]	[6.9]
	[25.9%]	[25.7%]	[26.9%]	[21.5%]	[100.0%]	[26.4%]	[24.0%]	[26.2%]	[23.5%]	[100.0%]
[Overseas]	[0.8]	[0.4]	[0.5]	[0.3]	[2.2]	[0.9]	[0.4]	[0.5]	[0.4]	[2.3]
	[37.4%]	[21.0%]	[24.6%]	[17.0%]	[100.0%]	[39.0%]	[18.2%]	[22.8%]	[20.1%]	[100.0%]
Cost of Sales	35.9	35.0	45.7	31.0	147.8	41.3	36.5	44.5	32.1	154.5
Sales Cost Ratio	35.6%	36.0%	37.5%	36.7%	36.5%	38.0%	38.1%	38.8%	35.7%	37.7%
Gross Operatin Profit	64.8	62.3	76.2	53.4	256.9	67.4	59.4	70.2	57.8	254.9
	25.2%	24.3%	29.7%	20.8%	100.0%	26.5%	23.3%	27.6%	22.7%	100.0%
SG & A Expenses	42.2	57.4	43.7	51.9	195.4	40.8	45.8	41.5	50.1	178.3
	21.6%	29.4%	22.4%	26.6%	100.0%	22.9%	25.7%	23.3%	28.1%	100.0%
R&D Expenses	16.1	28.4	16.4	22.0	83.0	15.9	16.5	15.1	18.1	65.7
	19.4%	34.2%	19.9%	26.5%	100.0%	24.2%	25.1%	23.0%	27.7%	100.0%
Except R&D Expenses	26.1	29.0	27.2	29.9	112.3	24.9	29.2	26.4	31.9	112.6
	23.3%	25.9%	24.2%	26.7%	100.0%	22.1%	26.0%	23.5%	28.4%	100.0%
Labor Costs	12.6	13.5	13.0	13.7	53.0	12.3	13.4	12.4	14.2	52.5
	23.9%	25.5%	24.7%	25.9%	100.0%	23.5%	25.6%	23.7%	27.2%	100.0%
Sales Promotion Expenses	2.2	3.3	2.9	3.4	11.9	1.7	3.5	2.7	3.2	11.3
	19.2%	27.9%	24.5%	28.5%	100.0%	15.5%	31.5%	24.4%	28.6%	100.0%
Amortization of Goodwill	2.5	2.5	2.5	2.5	10.1	2.5	2.5	2.5	2.5	10.1
	25.0%	25.0%	25.0%	25.0%	100.0%	25.0%	25.0%	25.0%	25.0%	100.0%
Others	8.6	9.6	8.6	10.2	37.2	8.2	9.7	8.7	11.8	38.6
	23.2%	25.9%	23.3%	27.6%	100.0%	21.4%	25.2%	22.6%	30.8%	100.0%
Operating Income	22.5	4.8	32.5	1.5	61.4	26.5	13.5	28.7	7.7	76.5
	36.7%	7.9%	52.9%	2.5%	100.0%	34.7%	17.7%	37.5%	10.1%	100.0%
Ordinary Income	23.0	4.8	32.4	1.2	61.6	26.7	13.6	28.9	7.2	76.6
	37.4%	7.9%	52.7%	2.0%	100.0%	34.9%	17.8%	37.7%	9.5%	100.0%
Net Income	11.3	2.1	19.0	(2.3)	30.2	14.6	8.0	16.5	(1.5)	37.7
	37.6%	7.2%	63.0%	(7.8%)	100.0%	38.9%	21.3%	43.9%	(4.0%)	100.0%

The each figure (excluding Cost of Sales) in the lower displays the progress rate.

(2) Sales of Main Products

[Billion yen]

	FY2009					FY2010				
	1Q Apr. to Jun.	2Q Jul. to Sep.	3Q Oct. to	4Q Jan. to	FY2009 Actual	1Q Apr. to Jun.	2Q Jul. to Sep.	3Q Oct. to	4Q Jan. to	FY2010 Actual
Ethical drugs	97.0	93.7	118.3	81.6	390.7	104.7	92.2	110.9	86.8	394.7
	24.8%	24.0%	30.3%	20.9%	100.0%	26.5%	23.4%	28.1%	22.0%	100.0%
Ethical drugs domestic sales	88.8	83.2	110.1	72.3	354.6	96.0	83.0	103.5	78.9	361.6
	25.1%	23.5%	31.1%	20.4%	100.0%	26.6%	23.0%	28.6%	21.8%	100.0%
Remicade	10.3	12.3	13.2	11.2	47.1	14.3	14.9	17.3	13.7	60.4
	21.9%	26.3%	28.0%	23.8%	100.0%	23.8%	24.8%	28.8%	22.7%	100.0%
Radicut	7.1	6.7	8.3	5.7	27.9	7.9	6.2	8.0	6.3	28.7
	25.6%	24.0%	30.0%	20.4%	100.0%	27.8%	21.9%	28.2%	22.1%	100.0%
Ceredist	4.4	3.9	5.1	3.3	16.8	4.8	4.1	5.1	3.9	18.0
	26.2%	23.7%	30.2%	19.9%	100.0%	26.6%	23.0%	28.3%	22.0%	100.0%
Anplag	5.0	4.4	5.7	3.1	18.3	4.5	3.7	4.7	3.4	16.4
	27.7%	23.9%	31.4%	17.0%	100.0%	27.5%	22.8%	28.8%	20.9%	100.0%
Urso	4.3	3.9	4.8	3.2	16.2	4.1	3.5	4.2	3.3	15.3
	26.5%	24.2%	29.5%	19.7%	100.0%	26.9%	23.3%	27.8%	22.0%	100.0%
Talion	2.3	1.7	3.0	3.4	10.6	2.6	2.0	3.5	5.1	13.4
	22.3%	16.6%	28.4%	32.7%	100.0%	19.8%	15.6%	26.5%	38.1%	100.0%
Maintate	2.8	2.5	3.3	2.2	11.0	3.2	2.7	3.4	2.8	12.3
	26.2%	23.4%	30.2%	20.2%	100.0%	26.3%	22.2%	28.4%	23.1%	100.0%
Depas	3.0	2.7	3.3	2.3	11.5	3.0	2.6	3.1	2.5	11.4
	26.7%	24.0%	28.7%	20.6%	100.0%	27.0%	23.1%	27.7%	22.2%	100.0%
Tanatril	3.1	2.6	3.3	1.9	11.1	2.7	2.2	2.7	1.9	9.6
	28.5%	23.4%	30.4%	17.7%	100.0%	28.5%	23.2%	28.3%	20.0%	100.0%
Herbesser	3.0	2.5	3.1	2.0	10.7	2.7	2.1	2.8	1.9	9.6
	28.0%	23.7%	29.5%	18.9%	100.0%	28.1%	22.6%	29.3%	20.0%	100.0%
Venoglubulin IH	2.5	2.4	2.9	1.7	9.6	2.3	2.1	2.8	2.1	9.6
	26.4%	24.9%	30.3%	18.4%	100.0%	24.9%	22.4%	29.9%	22.7%	100.0%
Liple	2.2	1.9	2.2	1.6	8.0	2.0	1.6	2.0	1.5	7.3
	27.5%	23.9%	28.5%	20.0%	100.0%	27.7%	23.1%	27.7%	21.5%	100.0%
Sermion	2.0	1.7	2.1	1.2	7.2	1.8	1.5	1.7	1.2	6.3
	28.3%	24.2%	29.7%	17.8%	100.0%	28.4%	23.5%	27.8%	20.3%	100.0%
Neuart	1.3	1.4	1.8	1.0	5.7	1.4	1.3	1.6	1.1	5.5
	24.3%	25.6%	32.1%	18.1%	100.0%	26.1%	23.3%	30.1%	20.5%	100.0%
Omeprason	1.5	1.3	1.6	1.0	5.5	1.3	1.1	1.3	1.0	4.8
	27.6%	23.9%	30.3%	18.2%	100.0%	28.3%	22.7%	28.5%	20.5%	100.0%
Novastan	0.7	0.7	0.8	0.5	2.8	0.9	0.7	0.8	0.5	3.1
	26.9%	24.7%	28.4%	20.0%	100.0%	29.2%	25.0%	27.4%	18.3%	100.0%
BIKEN products [Vaccine]*1	6.2	6.7	5.4	4.4	22.9	7.7	7.3	9.2	5.2	29.6
	27.3%	29.5%	23.7%	19.4%	100.0%	26.1%	24.8%	31.3%	17.8%	100.0%
Mearubik	4.9	2.8	1.0	2.8	11.7	4.9	2.5	1.4	3.2	12.2
	41.7%	24.5%	9.2%	24.6%	100.0%	40.6%	21.1%	11.6%	26.6%	100.0%
Influenza*1	0.0	2.4	3.7	0.1	6.3	0.0	1.9	5.7	(0.5)	7.1
	0.0%	38.0%	59.0%	3.1%	100.0%	0.0%	27.4%	80.2%	(7.6%)	100.0%
JEVIK V	0.3	0.6	0.3	0.6	2.0	1.7	1.9	1.6	1.5	6.9
	19.5%	33.6%	15.6%	31.3%	100.0%	25.6%	27.9%	23.9%	22.6%	100.0%
Tanabe Seiyaku Hanbai products *2	1.7	1.7	2.8	2.1	8.5	2.8	2.5	4.7	3.9	14.0
	21.1%	20.2%	33.0%	25.8%	100.0%	20.4%	18.1%	33.7%	27.9%	100.0%
Ethical drugs overseas sales	5.2	6.0	5.5	5.9	22.8	5.6	5.6	5.0	4.9	21.3
	23.0%	26.6%	24.4%	25.9%	100.0%	26.6%	26.4%	23.7%	23.3%	100.0%
Herbesser	1.1	1.2	1.1	1.0	4.6	1.2	1.2	1.0	1.1	4.6
	25.6%	27.4%	24.1%	22.8%	100.0%	25.9%	26.4%	23.4%	24.3%	100.0%
Argatroban (Novastan)	0.8	0.9	0.8	1.1	3.6	1.0	0.8	0.8	0.7	3.4
	23.1%	24.8%	22.0%	30.2%	100.0%	29.5%	23.5%	24.3%	22.8%	100.0%
Tanatril	0.4	0.5	0.4	0.4	1.8	0.5	0.4	0.4	0.3	1.8
	23.1%	30.6%	23.2%	23.1%	100.0%	30.0%	23.2%	27.0%	19.8%	100.0%
Anplag	0.3	0.2	0.3	0.1	1.1	0.1	0.2	0.0	0.2	0.6
	33.1%	20.7%	30.9%	15.4%	100.0%	22.6%	40.2%	3.7%	33.4%	100.0%
Vaccine	0.3	0.3	0.3	0.3	1.3	0.2	0.4	0.2	0.4	1.3
	25.7%	25.5%	23.9%	24.9%	100.0%	18.9%	30.0%	16.5%	34.6%	100.0%
Contracted manufacturing products *3	2.6	2.6	2.1	2.6	10.1	2.6	2.5	1.9	2.2	9.3
	25.7%	26.4%	21.6%	26.4%	100.0%	28.6%	27.0%	20.9%	23.5%	100.0%
Lincensing fee, etc.	0.3	1.7	0.3	0.6	3.1	0.2	1.0	0.4	0.6	2.4
	10.8%	54.5%	12.6%	22.1%	100.0%	11.3%	42.5%	17.6%	28.6%	100.0%
OTC products	1.1	1.5	1.2	1.0	4.9	1.2	1.5	1.5	1.0	5.4
	22.9%	30.6%	25.2%	21.3%	100.0%	23.7%	29.1%	28.2%	19.0%	100.0%
Total pharmaceuticals	98.1	95.2	119.6	82.6	395.7	106.0	93.8	112.5	87.8	400.2
	24.8%	24.1%	30.2%	20.9%	100.0%	26.5%	23.4%	28.1%	22.0%	100.0%

The each figures in the lower displays the progress rate.

*1: In FY2009, sales of influenza(H1N1)2009 vaccine are not included in sales of vaccine and influenza vaccine
Seasonal influenza vaccine of this year is composed of influenza(H1N1)2009 vaccine and other seeds.

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which are transferred from MTPC.

*3: Active pharmaceutical ingredients, and others ordered by other compnies.

5 State of New Product Development (as of May 10, 2011)

1. Pipeline in Japan

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin	Remarks
CNTO148 (Golimumab)	Anti-TNFα monoclonal antibody (Rheumatoid arthritis)	NDA filed (Jun. 2010)	US:Centocor Ortho Biotech	Co-development -Janssen Pharmaceutical K.K.
FTY720 (Fingolimod hydrochloride)	Sphingosine-1-phosphate receptor modulator (Multiple sclerosis*)	NDA filed (Dec. 2010)	In-house	Co-development -Novartis Pharma K.K.
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	NDA filed (Jan. 2011)	US:Vertex	
MP-513 (Teneligliptin)	DPP4 Inhibitor (Type 2 Diabetes mellitus)	Phase 3	In-house	
BK-4SP	Vaccine (Prophylaxis of pertussis, diphtheria, tetanus, and poliomyelitis)	Phase 3	The Research Foundation for Microbial Diseases of Osaka University	Co-development -The Research Foundation for Microbial Diseases of Osaka University
MP-214 (Cariprazine)	D3/D2 receptor antagonist (Schizophrenia)	Phase 2	Hungary: Gedeon-Richter	
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 Diabetes mellitus)	Phase 2	In-house	
MP-435	C5a receptor antagonist (Rheumatoid arthritis)	Phase 2	In-house	
MT-4666	α7nAChR agonist (Alzheimer's disease)	Phase 1	US: EnVivo Pharmaceuticals	

(2) Additional Indications

Development code/Product Name (Generic name)	Category (Indications)	Stage	Origin	Remarks
Venoglobulin IH (Polyethylene glycol treated human normal immunoglobulin)	Human immunoglobulin G (IgG2 deficiency)	sNDA filed (Dec. 1997)	In-house	
	(Systemic scleroderma)	Phase 3		
	(Myasthenia gravis*)	sNDA filed (Dec. 2010)		
Modiodal (Modafinil)	Psychoneurotic agent (Obstructive sleep apnea syndrome)	Filed (May 2010)	US: Cephalon	Co-development -Alfresa Pharma
MCI-9038 (Argatroban)	Thrombin inhibitor (Prevention of the blood clottingcoagulation in under dialysis and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia [HIT])	sNDA filed (Aug. 2010)	In-house	
Maintate (Bisoprolol)	Selective β1 antagonist (Chronic heart failure)	sNDA filed (Nov. 2010)	Germany : Merck KGaA	
AZANIN (Azathioprine)	Immunosuppressant (Systemic Vasculitis, systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, intractable rheumatic disease)	sNDA filed (Nov. 2010)	UK: GlaxoSmithKline	
Anti-D Human Immunogloblin	Anti-D Human Immunogloblin (Suppression of immunization of the D(Rho) factor [post partum, treatment through pregnancy or for parturition, abdominal bruise etc., and pregnancy around 28 weeks])	sNDA filed (Nov. 2010)	In-house	
Remicade (Infliximab[recombinant])	Anti-TNFα monoclonal antibody (Crohn's disease: dose escalation)	sNDA filed (Dec. 2010)	US: Centocor Ortho Biotech	
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house	
Cholebine (Colestimide(JAN))	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house	
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1		

*: Orphan drug designated

2. Pipelines Overseas

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Region	Stage	Origin	Remarks
LIVALO (Pitavastatin calcium)	HMG-CoA reductase inhibitor (Hypercholesterolemia, Familial hypercholesterolemia)	Taiwan	NDA filed (Apr. 2010)	Japan: Kowa	Filed by Tai Tien Pharmaceuticals
		Indonesia	NDA filed (Jun. 2010)		Filed by Tanabe Indonesia
MCI-196 (Colestilan(INN))	Non-absorbed phosphate binder (Hyperphosphatemia)	US, Europe	Phase 3	In-house	
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha	
MT-2832 (Lunacalcipol)	Vitamin D analog (Secondary hyperparathyroidism)	US, Canada	Phase 2	Canada: Cytochroma	
MCI-186 (Edaravone)	Free radical scavenger (Acute ischemic stroke)	Europe	Phase 2	In-house	
MP-513 (Teneligliptin)	DPP4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house	
		US	Phase 1		
GB-1057 (Human serum albumin[recombinant])	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house	
TA-8995	CETP inhibitor (Dyslipidemia)	Europe	Phase 1	In-house	
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house	
MP-136	PPAR alpha agonist (Dyslipidemia)	Europe	Phase 1	In-house	
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Europe	Phase 1	In-house	
MP-157	Angiotensin Type2 Receptor agonist (Hypertention)	Europe	Phase 1	In-house	
MT-1303	Sphingosine-1-phosphate receptor modulator (Multiple sclerosis)	Europe	Phase 1	In-house	

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Korea	Filed	Korea: JW Pharmaceutical (ex-Choongwae Pharma)
		US	Phase 3	US: Vivus
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 Diabetes mellitus)	US, Europe	Phase 3	US: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
	(Obesity)	US, Europe	Phase 2	
T-0047 (Firategrast)	Cell adhesion inhibitor [α4β7/α4β1 inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK:GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US:MediciNova
MKC-231	Neurogenesis enhancer (Depression/anxiety)	US	Phase 2	US:BrainCells
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
MKC-733	5-HT3 receptor agonist (Gastroesophageal reflux disease)	US	Phase 2	US: Edusa Pharmaceuticals
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase1	France:Negma (Sidem)
TT-138	β3 receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US:MediciNova
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase1	Japan: Maruho

4. Changes Since Previous Announcement on Jan. 28, 2011

(1) Own Development

Development code (Generic name)	Category (Indications)	As of Jan. 28, 2011	As of May 10, 2011
MCI-9038(Argatroban)	Thrombin inhibitor (Heparin-induced thrombocytopenia (HIT))	Filed in France, Spain (Nov. 2010)	Agreed to approval in France, Spain (Feb. 2011)
MP-157	Angiotensin Type2 Receptor agonist (Hypertention)	Not described	Europe Phase 1
MT-1303	Sphingosine-1-phosphate receptor modulator (Multiple sclerosis)	Not described	Europe Phase 1

(2) Licensing-out

Development code (Generic name)	Category (Indications)	As of Jan. 28, 2011	As of May 10, 2011
FTY720 (Fingolimod hydrochloride)	Sphingosine 1–phosphate receptor modulator (Multiple sclerosis)	Filed in Europe (Dec. 2009)	Approved in EU, Canada (Mar. 2011)
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Korea Phase 3	Filed in Korea (Jan. 2011)
MKC-733	5-HT3 receptor agonist (Gastroesophageal reflux disease)	Not described	US Phase 2
TA-2005 (Carmoterol)	Long-acting β2 receptor agonist (Asthma, COPD)	Europe Phase 2	Termination of Licensing Agreement (Jan. 2011)

5. Additional Information for State of New Product Development

(1) New Molecular Entities in Japan

Development code/Product Name (Generic name)	Information
CNTO148 (Golimumab)	CNTO148 is an anti-TNFα monoclonal antibody, licensed from Centocor Ortho Biotech(US), and co-developed with Janssen Pharmaceutical K.K. NDA was filed in June for rheumatoid arthritis with subcutaneous injections.
FTY720 (Fingolimod hydrochloride)	(Orphan drug designated in September, 2007) FTY720 is a sphingosine-1-phosphate receptor modulator and has been developed with Novartis Pharma K.K. NDA was filed in December 2010 for multiple sclerosis.
MP-424 (Telaprevir)	MP-424 is an orally-available product for treatment of chronic liver diseases due to hepatitis C virus infection, licensed from Vertex (US). This compound inhibits protease NS3/4 in hepatitis C virus. NDA was filed in January 2011.
MP-513 (Teneligliptin)	MP-513 is developed for the treatment of type-2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP4), thus accelerates the insulin secretion after meal intake. Clinical stage in Japan is Phase 3.
BK-4SP	Diphtheria toxoid-Tetanus toxoid-Bordetella pertussis antigen-Inactivated Poliovirus Combined Vaccine. Co-development with the Research Foundation for Microbial Diseases of Osaka University. Clinical stage is Phase 3.
MP-214 (Cariprazine)	MP-214 is a dopamine D3/D2 receptor antagonist, licensed from Gedeon-Richter (Hungary). Clinical stage is Phase 2 for schizophrenia.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. Clinical stage is Phase 2 for type2 diabetes mellitus.
MP-435	MP-435 is a C5a (complement factor) receptor antagonist which modulates the immune system. Clinical stage is Phase 2 for oral antirheumatoid drug.
MT-4666	MT-4666 is an α7 nACh receptor agonist, licensed from EnVivo pharmaceuticals Inc. (US). Clinical stage is Phase 1 for Alzheimer's disease.

(2) Additional Indications in Japan

Development code/Product Name (Generic name)	Information
Venoglobulin IH (Polyethylene glycol treated human normal immunogloblin)	(IgG2 deficiency) sNDA has been filed.
	(Diffuse systemic scleroderma) Clinical research in Japan demonstrated IV-IG was effective in improvement of skin manifestation, a primary endpoint of systemic scleroderma. Efficacy of IV-IG was also reported in overseas studies. Clinical stage is Phase 3. It was designated as an orphan drug at September in 2009.
	(Myasthenia gravis [Orphan drug designated in September 2009]) sNDA was filed in Dec. 2010.
Modiodal (Modafinil)	(Obstructive sleep apnea) sNDA was filed by Alfresa Pharma Corp. in May 2008. As a result of the consultation with PMDA, additional data was required. The additional data was submited in May 2010.
MCI-9038 (Argatoroban)	(Prevention of the blood coagulation in dialysis and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia [HIT]) sNDA has been filed in August 2010.
Remicade (Infliximab [recombinant])	(Crohn's disease) In order to verify the effectiveness of Remicade when administered in higher doses for patients showing an insufficient response to maintenance therapy. sNDA was filed in Dec. 2010.
Maintate* (Bisoprolol)	(Chronic heart failure) In Europe, the result of the large-scale CIBIS-II trials demonstrated that bisoprolol significantly decreased mortality in patients with chronic heart failure (NYHA III-IV). In Japan, sNDA was filed in November 2010.
AZANIN* (Azathioprine)	(Immunosuppressant) In Japan, sNDA was filed in November 2010, for Systemic Vasculitis, systemic lupus erythematosus, polymyositis/dermatomyositis, scleroderma, mixed connective tissue disease, Intractable rheumatic disease.
Anti-D Human Immunogloblin*	(Anti-D Human Immunogloblin) In Japan, sNDA was filed in November 2010, for suppression of immunization of the D(Rho) factor (post partum, treatment through pregnancy or for parturition, abdominal bruise etc., and pregnancy around 28 weeks)
Radicut (Edaravone)	(Amyotrophic lateral sclerosis [Orphan drug designated in June, 2005]) Clinical stage is Phase 3.
Cholebine (Colestimide(JAN))	(Type 2 diabetes mellitus) Clinical stage is Phase 2.
	(Hyperphosphatemia) Clinical stage is Phase 1.

*; Correspondent to the review committee on unapproved drugs and indications with high medical needs

(3) New Molecular Entities Overseas

Development code/Product Name (Generic name)	Information
LIVALO (Pitavastatin calcium)	LIVALO is HMG-CoA reductase inhibitor, licensed from Kowa Co., Ltd. (Japan) in August 2009. NDAs have been filed in Taiwan and Indonesia by the overseas subsidiaries. It is marketed by Kowa Co., Ltd. in Japan under the brand name, LIVALO®.
MCI-196 （Colestilan(INN)）	MCI-196 is anion-exchange resin, and has been developed for the treatment of hyperphosphatemia in patients on dialysis in Europe and the US. Clinical stage is Phase 3. It is marketed in Japan for the treatment of hypercholesterolemia, under the brand name of CHOLEBINE®.
MP-146	MP-146 is spherical carbon adsorbent, licensed from KUREHA CORPORATION (Japan) in November 2006. Clinical stage is Phase 3 for Chronic Kidney Disease patients in Europe, North America and South America. It has been marketed by Daiichi Sankyo Co. Ltd. in Japan from 1991 under the brand name, KREMEZIN®. In April 2011, Mitsubishi Tanabe Pharma Corporation has succeeded its marketing from Daiichi Sankyo.
MT-2832 (Lunacalcipol)	MT-2832 was licensed from Cytochroma Inc. (Canada) in July 2008. MT-2832 is a strong activator of the vitamin D signaling pathway and has a resistance characteristics to CYP24, intracellular enzyme responsible for catabolism of Vitamin D hormones. Clinical stage is Phase 2 for secondary hyperparathyroidism in patients with chronic kidney disease in Canada.
MCI-186 （Edaravone）	MCI-186 is the world's first cerebral neuroprotectant (free radical scavenger). Clinical stage in Europe is Phase 2 for the acute ischemic stroke. It is marketed in Japan under the brand name, Radicut®.
MP-513 （Teneligliptin）	MP-513 is developed for the treatment of type-2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP4), thus accelerates the insulin secretion after meal intake. Clinical stages in the US and Europe are Phase1 and Phase 2, respectively.
GB-1057 （Human serum albumin [recombinant]）	GB-1057 is a recombinant human serum albumin. Clinical stage is Phase 1 as a stabilizing agent in the US.
TA-8995	TA-8995 is a CETP inhibitor that has raising the HDL-C and lowering the LDL-C effects. Clinical stage is Phase 1 in Europe.
MP-124	MP-124 is a PARP inhibitor that has neuroprotective effect. Clinical stages in the US and Canada are Phase 1 for acute ischemic stroke.
MP-136	MP-136 is a PPAR alpha agonist. Clinical stage is Phase 1 in Europe for dyslipidemia.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase 1 in Europe for hypertension.
MP-157	MP-157 is a Angiotensin Type2 Receptor Agonist. Clinical stage is Phase 1 in Europe for hypertention.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor modulator. Clinical stage is Phase1 in Europe for multiple sclerosis.

(4) Licensing-out

Development code/Product Name (Generic name)	Information
TA-1790 (Avanafil)	TA-1790 is developed for the treatment of erectile dysfunction by Mitsubishi Tanabe Pharma, which is expected to have a quick onset and fewer side effects. Clinical trial stage is Phase 3 in the US and filed in Korea.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. Phase 3 clinical trials in diabetes mellitus in Europe and the US are underway by Johnson & Johnson Pharmaceutical Reseach & Development, L.L.C. Phase 2 clinical trials in obesity in Europe and the US are completed.
T-0047(Firategrast)	T-0047 inhibits the cell adhesion and cell migration processes of white blood cells in inflammatory region. Phase 2 trial is conducted by GSK in Europe, Canada, Australia, and New Zealand.
MKC-242	MKC-242 is a serotonin 1A receptor agonist, used to treat psychiatric disorders such as anxiety and depression. This compound is expected to reveal rapid onset with low possibility of dependency. Medici Nova Inc.(US) is conducting Phase 2 clinical trials in patients with generalized anxiety disorder or insomnia.
MKC-231	MKC-231 is a neurogenesis enhancer. Phase 2 study in major depression is underway by BrainCells Inc.(US).
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscle. Clinical trial stage in Japan is Phase 2 by Senju Pharmaceutical Co. Ltd..
MT-210	MP-210 is a 5-HT2A/ Sigma 2 receptor antagonist. Clinical trial stage is Phase 2 in Europe by Cyrenaic (France).
MKC-733	MKC-733 modulates gastrointestinal motility by agonising serotonin 5-HT3 receptors. Edusa Pharmaceuticals is conducting in the US a phase 2 clinical trial in patients with gastroesophageal reflux disease at night.
sTU-199 (Tenatoprazole)	sTU-199 is an isomer of TU-199, developed in Japan, and licensed to Negma (France). Pharmacokinetic/pharmacodynamic results from Phase 1 clinical trials in Europe and the US demonstrated that sTU-199 controlled gastric acid secretion at nighttime in patients receiving this compound once-daily, with the long terminal half-life. It is expected that this compound will reveal rapid improvement for non-erosive reflux disease. Sidem Pharma, a subsidiary of Negma, is conducting phase 1 trial for gastroesophageal reflux dsease in Europe.
TT-138	TT-138 is a β3 receptor agonist used to treat pollakiuria and urinary incontinence. Phase 1 study is conducted by Medici Nova Inc. in the US.
TA-7906	TA-7906 is a PDE4 inhibitor. Clinical trial stage is Phase1 for the treatment of atopic dermatitis in Japan by Maruho Co. Ltd.

6 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of FY2010	End of FY2009	Increase (decrease)	Notes
Consolidated subsidiaries	**28**	27	1	Increase: Guangdong Tanabe Pharmaceutical
Noconsolidated subsidiaries	**3**	6	(3)	Decrease: Guangdong Tanabe Pharmaceutical., Koei Shoji, Tokyo Tanabe Shoji
Affiliated companies	**3**	4	(1)	Decrease: Sun Chemical
Total	**34**	37	(3)	

(2) Consolidated Subsidiaries [As of March 31, 2011]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Benesis Corporation	3,000	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
2	Mitsubishi Tanabe Pharma Factory Ltd.	1,130	100.0	[-]	End of Mar.	Manufacture of pharmaceuticals and related products
3	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KPW 2,100,000,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
4	Mitsubishi Pharma (Guangzhou) Co., Ltd.	US$12,000,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
5	Tianjin Tanabe Seiyaku Co., Ltd.	US$12,000,000	66.7	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
6	Yoshitomiyakuhin Corporation	385	100.0	[-]	End of Mar.	Provision of information about pharmaceuticals
7	MP-Logistics Corporation	95	65.0	[-]	End of Mar.	Distribution, warehouse operations
8	BIPHA CORPORATION	7,500	51.0	[-]	End of Mar.	Manufacture of pharmaceuticals
9	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	400	100.0	[-]	End of Mar.	Manufacture of pharmaceuticals
10	Tanabe Seiyaku Hanbai., Ltd.	169	92.9	[7.9]	End of Mar.	Sale of generic pharmaceuticals and related products
11	Tanabe R&D Service Co., Ltd.	44	100.0	[-]	End of Mar.	Support of R&D regarding pharmaceuticals
12	Tanabe Total Service Co., Ltd.	90	100.0	[-]	End of Mar.	Real estate management and etc.
13	MP Healthcare Venture Management, Inc.	US$100	65.0	[-]	End of Dec.	Investments in bio-ventures
14	Mitsubishi Tanabe Pharma Holdings America, Inc.	US$166	100.0	[-]	End of Dec.	Management of group companies in US
15	Mitsubishi Tanabe Pharma Development America, Inc.	US$100	100.0	[100.0]	End of Dec.	R&D of pharmaceuticals
16	Tanabe Research Laboratories U.S.A., Inc.	US$3,000,000	100.0	[100.0]	End of Dec.	R&D of pharmaceuticals
17	Tanabe U.S.A., Inc.	US$1,400,000	100.0	[100.0]	End of Dec.	Sale of chemicals
18	Mitsubishi Tanabe Pharma America, Inc.	US$100	100.0	[100.0]	End of Dec.	Sale of pharmaceuticals
19	Mitsubishi Pharma Research & Development (Beijing) Co., Ltd.	US$1,000,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
20	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0	[-]	End of Dec.	Sale of pharmaceuticals
21	Taiwan Tanabe Seiyaku Co., Ltd.	NT$90,000,000.00	65.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
22	Tai Tien Pharmaceuticals Co., Ltd.	NT$20,000,000.00	65.0	[-]	End of Dec.	Sale of pharmaceuticals
23	P.T. Tanabe Indonesia	US$2,500,000	99.6	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
24	Mitsubishi Pharma Europe Ltd.	£4,632,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
25	Mitsubishi Pharma Deutschland GmbH	EUR 25,000	100.0	[100.0]	End of Dec.	Sale of pharmaceuticals
26	Tanabe Europe N.V.	EUR 260,330	100.0	[-]	End of Dec.	Sale of chemicals

Note: Aside from the companies mentioned above, there are two consolidated companies under the liquidations.

(3) Nonconsolidated Subsidiaries Accounted for by the Equity Method [As of March 31, 2011]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Choseido Pharmaceutical Co.,Ltd.	340	52.5	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
2	Hoshienu Pharmaceutical Co.,Ltd.	75	52.5	[52.5]	End of Mar.	Manufacture and sale of pharmaceuticals

(4) Affiliated Companies Accounted for by the Equity Method [As of March 31, 2011]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	API Corporation	4,000	47.7	[-]	End of Mar.	Manufacture and sale of API
2	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	The End of March, 2011	The End of March, 2010
Issued	**561,417,916**	561,417,916
The company's own shares at the end of the period	**353,152**	256,440
Number of shares outstanding at the end of the period	**561,064,764**	561,161,476
Average number of the company's own share	**307,141**	253,814
Average number of shares outstanding	**561,110,775**	561,164,102

(2) Status of Major Shareholders

Rank	Name of Shareholders	The End of March, 2011		The End of March, 2010		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	The Master Trust of Japan, Ltd.	25,490	4.54%	2	32,043	5.71%
3	Japan Trustee Services Bank, Ltd.	17,169	3.06%	3	25,237	4.50%
4	Nippon Life Insurance Company	15,875	2.83%	4	15,875	2.83%
5	Nipro Corporation	7,642	1.36%	5	8,030	1.43%
6	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	6	7,254	1.29%
7	Goldman Sachs & Company Regular Account	7,116	1.27%	-	213	0.04%
8	JP Morgan Chase Bank, N.A., 385147	7,100	1.26%	7	6,850	1.22%
9	Tokyo Marine & Nichido Fire Insurance Co., Ltd.	5,218	0.93%	8	5,218	0.93%
10	Pershing-Div. of DLJ Secs. Corp.	4,355	0.78%	13	3,021	0.54%

(3) Ownership and Distribution of Shares

	The End of March, 2011			The End of March, 2010		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial Institutions	62	90,522	16.13%	71	110,681	19.75%
Foreign Corporations and Others	391	100,839	17.97%	402	79,225	14.13%
Individuals and Others	11,460	26,104	4.65%	9,724	28,289	5.05%
Other Corporations	284	342,679	61.05%	220	341,060	60.85%
Securities Firms	38	1,148	0.20%	31	1,239	0.22%
Total	12,235	561,293	100.00%	10,448	560,494	100.00%
Less than Trading Unit	-	124	-	-	923	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stock (353 thousands shares at the end of March, 2011 and 256 thousands shares at the end of March, 2010)

④ Trend of Divended and Stock Price

	FY2007 *1	FY2008 *2	FY2009 *2	FY2010 *2	FY2011 Estimate *2
Dividends per Share (Yen)	26	28	28	28	28
Dividend Payout Ratio(%)	44.0	43.0	39.0	32.9	34.5
Stock Price at end of FY	1,161	971	1,320	1,350	-
Market Capitalization (Billion Yen)	6,518	5,451	7,410	7,579	-

*1: The interim dividends of the former Tanabe Seiyaku (¥13) and the year-end dividends of Mitsubishi Tanabe Pharma (¥13) are used for the FY2007 dividends. The dividend payout ratio is calculated using Mitsubishi Tanabe Pharma's net income for the second half of the fiscal year (less amortization of goodwill) and Mitsubishi Tanabe Pharma's year-end dividends.

*2: The dividend payout ratio is calculated using Mitsubishi Tanabe Pharma's net income for the fiscal year (less amortization of goodwill) and annual dividends.

3 Number of Employees

	End of FY2007	End of FY2008	End of FY2009	End of FY2010	End of FY2010 Estimate
Consolidated	10,361	10,030	9,266	9,198	9,300
Non-consolidated	6,266	5,715	5,186	4,957	4,840

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNF α monoclonal antibody (Treatment of rheumatoid arthritis (RA), active Crohn's disease(CD), Behcet's disease with refractory uveoretinitis, psoriasis and ankylosing spondylitis, moderate to severe ulcerative colitis)

Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for two months with a single administration. It was approved in Japan for the treatment of Behcet's disease with refractory uveoretinitis in January 2007 and for the maintenance treatment of CD in November 2007. Increase of the dosage/shortage of administration interval and the effect on prevention of structural joint damage for the treatment of RA were approved in July 2009. Remicade additionally received approvals for psoriasis in January 2010, for ankylosing spondylitis in April 2010, and for ulceractive colitis in June 2010.
Origin: Centocor Ortho Biotech

Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)

Radicut is the world's first brain protecting agent (free radical scavemger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administrated for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was approved in January and launched in May 2010.

Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration

Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. In October 2009, An additional formulation, orally disintegrating tablets, was approved in June and launched in October 2009.

Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)

Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as lcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of ollateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels. The downsized tablet which is convenient for elderly patients was approved in August 2007.

Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions

Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in human body. Urso has effects of hapatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.

Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders

Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007.
Origin: Ube Industries

Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β1 Antagonist (Treatment of angina pectoris, hypertension, and arrhythmias)

Maintate is a representative β -blocker used in more than 85 countries around the world. It exhibits high selectivity for β 1 receptor and excellent phamacokinetics profiles. It has high efficacy and safety, and there is evidence for its cardioprotective action.
Origin: Merck KGaA

Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent

Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for pychosomatic disease, neurosisas, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.

Tanatril (Imidapril)	Launch: Dec. 1993	Category	ACE Inhibitor (Treatment of hypertension)

Tanatril shows excellent blood pressure control with effective organ protection as well as minimal incidence of dry cough, a common side effect of ACE inhibitors. With the approval of an additional indication in 2002, it became the first drug in Japan approved for diabetic nephropathy with type I diabetes mellitus.

Herbesser (Diltiazem)	Launch: Feb. 1974	Category	Calcium antagonist (Treatment of angina pectoris and hypertension)

Herbesser is a representative calcium antagonist that is used in more than 110 countries around the world. In addition to a blood pressure lowering effect, it has a cardioprotective action in patients with hypertension or angina pectoris by reducing the cardiac load through a heart rate lowering effect and by increasing the oxygen supply through a coronary vasodilating effect.

Venoglobulin IH (Human immunoglobulin)	Launch: Jan. 1992	Category	Plasma derivatives

Venoglobulin IH is intravenous human immunoglobulin derived from donated plasma in Japan. It shows high efficacy on erious infectious diseases in combined administration with anti-bacterial agent due to its opsonic, immuno-bacteriolytic and antibody-dependent cytotoxic effects and neutralizing effects on toxics and viruses. In October 2010, the indications for improvement of muscle weakness associated with polymyositis or dermatomyositis were added, and it is expected to be a new treatment option for the diseases that contribute better QOL for patients.

Liple (Arprostadil)	Launch: Nov. 1988	Category	Chronic arterial occlusion / Circulatory disturbance (PGE1)

Liple, the world's first DDS (Drug Delivery System) agent of intravenous PGE1, improves the peripheral circulatory disturbance and skin ulcer in chronic arterial occlusive disease and diabetes by its direct vasolidating effects. DDS maximizes the therapeutic effects and simutaneously minimizes the adverse effects of PGE1.

Sermion (Nicergoline)	Launch: Jun. 1988	Category	Cerebral circulation and metabolism ameliorator

Sermion ameliorates blood flow and metabolism in the brain. It is used to treat sequela of cerebral infarction. In 1998, its effectiveness was confirmed in a reevaluation by the Ministry of Health and Welfare in Japan. In "the treatment guidelines for strokes in 2009," Sermion was recommended as a treatment drug for chronic cerebral infarction.
Origin: Pfizer

Neuart (Anti-thrombin III)	Launch: Jun. 1987	Category	Plasma derivatives (Anticoagulant agent)

Neuart is highly purified human anti-thrombin III derived from donated plasma in Japan. It shows strong anticoagulant effects in the treatment of DIC patients by inhibiting various kinds of activated serine protease including thrombin.

Omeprazon (Omeprazole)	Launch: Apr. 1991	Category	Proton pump inhibitor (Antiulcerogenic agent)

Omeprazon is the world's first proton pump inhibitor that suppresses gastric acid secretion. It strongly and sustainably blocks the final step in gastric acid production results in reducing gastric acidity. Omeprazon has excellent efficacy for gastric ulcer, duodenal ulcer and reflux esophagitis. Additional indications for non-erosive reflux disease (NERD) and secondary eradication of Hellicobacter pylori were approved in May and August 2007, respectively.
Origin: AstraZeneca

Novastan (Argatroban)	Launch: June 1990	Category	Selective Antithrombin Agents

Novastan is a fully synthesized, selective thrombin inhibitor. In Japan, it was launched in June, 1990 and has been approved for the treatment of limb ulcers, rest pain and a sensation of cold in chronic arterial occlusive disease, the acute treatment of neurological symptoms and activities of daily living for patients with acute-phase cerebral thrombosis, and the prevention of blood clotting in the circuit during hemodialysis in the patients with congenitally decreased antithrombin III levels. In July 2008, it was also approved for the prophylaxis of thrombosis in the patients with type 2 heparin-induced thrombocytopenia (HIT). In overseas market, it was approved by the FDA in 2000 for the prophylaxis or treatment of thrombosis in patient with HIT and has since been approved in nine countries for the same indications.

Mearubik (Live Attenuated Measles and Rubella Vaccine)	Launch: Dec. 2005	Category	Prevention of measles and rubella

Mearubik is the combination vaccine for measles and rubella, and children are able to receive both measles and rubella shot at a time with Mearubik. It is expected to contribute enhancement of immunization rate for measles and rubella in Japan.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

JEBIK V (Cell Culture-derived Japanese Encephalitis	Launch: Jan. 2009	Category	Prevention of Japanese encephalitis

JEBIK V is a freeze-dried preparation containing inactivated Japanese encephalitis virus derived from Vero cells which were used in the manufacturing process as a host to increase the virus. A freeze-dried prepared vaccine is available in routine vaccination. Accordingly, it is expected to increase in number of vaccinated persons.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

Kremezin	Launch: Apr. 2011	Category	Chronic renal failure

Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC.
Origin, Manufacturer and distributor: Kureha

News Releases

The major news releases after October, 2010 are as follows.
Please refer to the Company's website for the details. (http://www.mt-pharma.co.jp/e/index.php)

Date	Contents
October 12, 2010	Launch New 1000 mg Dosage Formulations of Pazucross Injectable New Quinolone Antibacterial Agents on October 13
October 27, 2010	Approval of Additional Indication of Venoglobulin IH 5% I.V., Human Immunoglobulin G for the Treatment of Polymyositis and Dermatomyositis
November 25, 2010	Newly Launch of Generic Drugs *
December 14, 2010	Commencement of R&D Partnership with Anaphore for Atrimer™ Technology (Novel Trivalent Proteins)
December 20, 2010	Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis Treatment
December 21, 2010	Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea
January 11, 2011	"Kremezin", Drug for Chronic Renal Failure Transfer of Marketing Rights in Japan
January 26, 2011	Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes)
January 28, 2011	Application Submitted in Japan for MP-424 a Novel Chronic Hepatitis C Treatment
January 28, 2011	Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market
Feburary 22, 2011	Notice Regarding Voluntary Recall and Termination of Manufacturing and Merketing of Serapeptitase
March 1, 2011	Notice Regarding Transfer of Kyusyu Blanch *
March 7, 2011	Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku Hanbai
March 11, 2011	Open Innovation Laboratory for Drug Discovery and Development by Mitsubishi Tanabe Pharma and Kyoto University -Basic and Clinical Reseach Project for CKD Drugs-
March 14, 2011	Mitsubishi Tanabe Pharma Support Japan Earthquake Relief Efforts
March 15, 2011	Impact of the 2011 off the Pacific coast of Tohoku Earthquake
March 28, 2011	Novartis Receives European Commision Approval for FTY720, the First Oral Multiple Sclerosis Treatment for Use in the EU
March 30, 2011	Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Notice)
April 11, 2011	Impact of the Great East Japan Earthquake (3rd Notice)
April 27, 2011	Summary of the Quality Control Incident
April 27, 2011	Partial Return of Executive Compensation
April 27, 2011	Change of Directors, and Organization
April 27, 2011	Change of Directors of Mitsubishi Tanabe Pharma Factory *

*: Only in Japanese